Total Payments
$2,140
2024 Payments
$798.68
Companies
19
Transactions
107
Medicare Patients
2,647
Medicare Billing
$462,140
Payment Breakdown by Category
Food & Beverage$1,726 (80.6%)
Education$414.58 (19.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,726 | 85 | 80.6% |
| Education | $414.58 | 22 | 19.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $508.78 | 30 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $284.11 | 17 | $0 (2024) |
| Astellas Pharma US Inc | $254.41 | 10 | $0 (2024) |
| ABBVIE INC. | $173.15 | 11 | $0 (2024) |
| Merck Sharp & Dohme LLC | $163.09 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $123.60 | 1 | $0 (2023) |
| Lilly USA, LLC | $117.45 | 1 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $111.32 | 6 | $0 (2023) |
| Celgene Corporation | $74.90 | 4 | $0 (2024) |
| Daiichi Sankyo Inc. | $65.65 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $798.68 | 40 | PFIZER INC. ($223.85) |
| 2023 | $623.46 | 24 | PFIZER INC. ($143.55) |
| 2022 | $504.51 | 30 | Novartis Pharmaceuticals Corporation ($144.89) |
| 2021 | $171.41 | 10 | Novartis Pharmaceuticals Corporation ($43.89) |
| 2019 | $14.63 | 1 | PFIZER INC. ($14.63) |
| 2017 | $27.68 | 2 | Genentech USA, Inc. ($13.94) |
All Payment Transactions
107 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.24 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/02/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.25 | General |
| Category: Hematology | ||||||
| 10/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | PFIZER INC. | TALZENNA (Drug), XTANDI | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $117.45 | General |
| Category: Oncology | ||||||
| 09/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | PFIZER INC. | INLYTA (Drug), TALZENNA, XTANDI | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Oncology | ||||||
| 08/07/2024 | PFIZER INC. | INLYTA (Drug), TALZENNA, XTANDI | Food and Beverage | In-kind items and services | $4.45 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $11.55 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $14.17 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 703 | 1,387 | $576,106 | $111,556 |
| 2022 | 10 | 639 | 1,503 | $278,254 | $125,093 |
| 2021 | 9 | 633 | 1,467 | $265,488 | $120,032 |
| 2020 | 10 | 672 | 1,549 | $282,752 | $105,459 |
Total Patients
2,647
Total Services
5,906
Medicare Billing
$462,140
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 114 | 481 | $244,620 | $50,596 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 207 | 458 | $173,512 | $33,049 | 19.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 152 | 199 | $51,781 | $9,416 | 18.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $32,758 | $5,438 | 16.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $29,216 | $5,164 | 17.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 32 | $21,145 | $4,000 | 18.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 28 | $6,311 | $1,670 | 26.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 34 | 36 | $8,125 | $1,311 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 38 | 39 | $6,768 | $813.23 | 12.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 17 | $1,870 | $99.28 | 5.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 89 | 592 | $129,056 | $62,039 | 48.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 192 | 461 | $74,682 | $30,724 | 41.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 174 | 237 | $26,070 | $10,816 | 41.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 34 | 37 | $11,618 | $5,601 | 48.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 48 | 48 | $12,000 | $4,540 | 37.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $8,164 | $3,554 | 43.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 28 | $4,480 | $2,187 | 48.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 16 | $3,488 | $1,796 | 51.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 27 | $3,024 | $1,465 | 48.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $2,756 | $1,343 | 48.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 18 | 18 | $2,916 | $1,027 | 35.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 85 | 542 | $118,156 | $58,066 | 49.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 186 | 424 | $68,688 | $28,782 | 41.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 193 | 272 | $29,920 | $11,978 | 40.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 66 | 66 | $16,500 | $6,301 | 38.2% |
About Dr. Kristin Thorp, MD
Dr. Kristin Thorp, MD is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1700927142.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kristin Thorp, MD has received a total of $2,140 in payments from pharmaceutical and medical device companies, with $798.68 received in 2024. These payments were reported across 107 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($1,726).
As a Medicare-enrolled provider, Thorp has provided services to 2,647 Medicare beneficiaries, totaling 5,906 services with total Medicare billing of $462,140. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 02/09/2007
- Last Updated 05/21/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700927142
Products in Payments
- IBRANCE (Drug) $352.03
- IMBRUVICA (Drug) $178.48
- KEYTRUDA (Biological) $163.09
- LYNPARZA (Drug) $123.60
- JAYPIRCA (Drug) $117.45
- VENCLEXTA (Drug) $104.17
- MEKINIST (Drug) $68.32
- XTANDI (Drug) $63.16
- KISQALI (Drug) $60.26
- OPDIVO (Biological) $56.70
- INLYTA (Drug) $51.54
- Xtandi (Drug) $50.34
- TECENTRIQ (Biological) $48.81
- PIQRAY (Drug) $44.48
- PADCEV (Drug) $40.57
- Pomalyst (Drug) $38.41
- BRAFTOVI (Drug) $36.92
- REBLOZYL (Biological) $36.49
- PLUVICTO (Drug) $30.34
- PADCEV (Biological) $24.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Hematology & Oncology $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Hematology & Oncology $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Hematology & Oncology $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Hematology & Oncology $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791
Hematology & Oncology $5,791